Hansa Biopharma enters into €115 million licensing agreement with SERB Pharmaceuticals for IDEFIRIX in Europe and MENA
PR Newswire
LUND, Sweden, May 19, 2026
The agreement covers the European Union, United Kingdom, Switzerland, Norway, Liechtenstein, Iceland and the MENA regionSignificantly enhances Hansa's financial position, ensuring a robust U.S. launch and provides path to profitability, subject to US approvalSERB has a substantial European commercial presence and a successful track record in critical care and rare disease commercialization LUND, Sweden, May 19, 2026 /PRNewswire/ -- Hansa Biopharma AB ("Hansa" or "the Company") (NASDAQ STOCKHOLM: HNSA) and SERB S.A. ("SERB") today announced an exclusive licensing agreement for development and commercialization of IDEFIRIX (imlifidase) in the European Union (EU), United Kingdom (UK), Switzerland, Norway, Liechtenstein, Iceland and MENA (Middle East and North Africa) regions.
View original content:https://www.prnewswire.com/news-releases/hansa-biopharma-enters-into-115-million-licensing-agreement-with-serb-pharmaceuticals-for-idefirix-in-europe-and-mena-302775762.htmlSOURCE Hansa Biopharma AB
